CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice

Objective—The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites of inflammation. Antagonizing CXCR3 may be a strategy to inhibit inflammation-induced leukocyte migration and subsequently reduce atherosclerosis. We used the CXCR3 specific antagonist NBI-74330 to block CXCR3-mediated signaling in peritonitis and diet-induced atherosclerosis. Methods and Results—Antagonizing CXCR3 with NBI-74330 resulted in a significant reduction in CD4+ T cell and macrophage migration to the peritoneal cavity, which was as shown in ex vivo migration studies totally CXCR3 dependent. Atherosclerotic lesion formation in the aortic valve leaflet area and the entire aorta was significantly inhibited in NBI-74330 treated mice. Lymph nodes draining from the aortic arch were significantly smaller in treated mice and were enriched in regulatory T cells and contained fewer activated T cells, whereas the markers for regulatory T cells within the lesion were enhanced after NBI-74330 treatment. Conclusion—This study shows for the first time that treatment with a CXCR3 antagonist results in attenuating atherosclerotic lesion formation by blocking direct migration of CXCR3+ effector cells from the circulation into the atherosclerotic plaque and by beneficially modulating the inflammatory response in the lesion and the lymph nodes draining from the atherosclerotic lesion.

[1]  H. Makino,et al.  Selective recruitment of CXCR3+ and CCR5+ CCR4+ T cells into synovial tissue in patients with rheumatoid arthritis. , 2006, Acta medica Okayama.

[2]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[3]  R. Terkeltaub,et al.  Interleukin-8 and its receptor CXCR2 in atherosclerosis , 2000, Immunologic research.

[4]  M. Neurath,et al.  Transforming growth factor β induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis , 2005, Gut.

[5]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[6]  J. Jukema,et al.  Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? , 2007, Current pharmaceutical design.

[7]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[8]  J. Mudgett,et al.  Antibody‐mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation , 2003, Journal of leukocyte biology.

[9]  C. Berek,et al.  Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus , 2005, Arthritis research & therapy.

[10]  F. Mach,et al.  Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo , 2005, Circulation.

[11]  S. Zheng,et al.  IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.

[12]  Christian Weber,et al.  Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[13]  P. Libby,et al.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.

[14]  E. Butcher,et al.  Differential Chemokine Responses and Homing Patterns of Murine TCRαβ NKT Cell Subsets 1 , 2003, The Journal of Immunology.

[15]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[16]  J. Malin,et al.  Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing–remitting multiple sclerosis , 2002, Journal of Neuroimmunology.

[17]  H. Fujiwara,et al.  HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  T. V. van Berkel,et al.  Induction of Rapid Atherogenesis by Perivascular Carotid Collar Placement in Apolipoprotein E–Deficient and Low-Density Lipoprotein Receptor–Deficient Mice , 2001, Circulation.

[19]  R. Steinman,et al.  Dendritic cells with TGF-β1 differentiate naïve CD4+CD25− T cells into islet-protective Foxp3+ regulatory T cells , 2007, Proceedings of the National Academy of Sciences.

[20]  D. Möbest,et al.  Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. , 1997, Blood.

[21]  J. Sedgwick,et al.  Tumor Necrosis Factor–dependent Segmental Control of MIG Expression by High Endothelial Venules in Inflamed Lymph Nodes Regulates Monocyte Recruitment , 2001, The Journal of experimental medicine.

[22]  A. Zernecke,et al.  Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[24]  F. Tacke,et al.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Flynn,et al.  The Chemokine Receptor CXCR3 Attenuates the Control of Chronic Mycobacterium tuberculosis Infection in BALB/c Mice1 , 2007, The Journal of Immunology.

[26]  J. Christensen,et al.  CXCL10 Is the Key Ligand for CXCR3 on CD8+ Effector T Cells Involved in Immune Surveillance of the Lymphocytic Choriomeningitis Virus-Infected Central Nervous System1 , 2006, The Journal of Immunology.

[27]  Albert Zlotnik,et al.  Pharmacological Characterization of CXC Chemokine Receptor 3 Ligands and a Small Molecule Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  A. Zernecke,et al.  Chemokines: Inflammatory mediators of atherosclerosis , 2006, Archives of physiology and biochemistry.

[29]  R. Flavell,et al.  TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Nose,et al.  Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts , 2005, Clinical and experimental immunology.

[32]  M. Munks,et al.  CXCR3-Dependent Recruitment of Antigen-Specific T Lymphocytes to the Liver during Murine Cytomegalovirus Infection , 2006, Journal of Virology.

[33]  W. van Eden,et al.  Induction of Oral Tolerance to Oxidized Low-Density Lipoprotein Ameliorates Atherosclerosis , 2006, Circulation.

[34]  K. Moore,et al.  Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.